QLT Inc. (TSX:QLT) lowered its revenue targets for 2010 Wednesday on reduced sales of its key product Visudyne, a treatment for macular degeneration of the eye. The company, which is an anchor in the B.C. biotech sector, posted revenue of $8.
Read more >